• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US Contraceptive Drugs Market

    ID: MRFR/Pharma/15186-HCR
    100 Pages
    Garvit Vyas
    September 2025

    US Contraceptive Drugs Market Research Report By Drug Type (Oral Contraceptives, Injectable Contraceptives, Implantable Contraceptives, Intrauterine Devices, Emergency Contraceptives), By Mechanism of Action (Hormonal, Barrier, Intrauterine, Surgical, Natural), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Specialty Clinics, Direct Sales) and By End User (Women, Healthcare Providers, Educational Institutions) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Contraceptive Drugs Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    US Contraceptive Drugs Market Summary

    The US Contraceptive Drugs market is projected to grow from 4.87 USD Billion in 2024 to 7.2 USD Billion by 2035.

    Key Market Trends & Highlights

    US Contraceptive Drugs Key Trends and Highlights

    • The market is expected to witness a compound annual growth rate (CAGR) of 3.62% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 7.2 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 4.87 USD Billion, reflecting a solid foundation for future expansion.
    • Growing adoption of contraceptive methods due to increasing awareness of reproductive health is a major market driver.

    Market Size & Forecast

    2024 Market Size 4.87 (USD Billion)
    2035 Market Size 7.2 (USD Billion)
    CAGR (2025-2035) 3.62%

    Major Players

    Teva Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, Novartis, Merck, HRA Pharma, Perrigo, Pfizer, Amgen, Allergan, Galderma, Johnson and Johnson, Mylan, Bayer, Sun Pharmaceutical

    US Contraceptive Drugs Market Trends

    The US contraceptive drugs market is witnessing significant trends influenced by various market drivers. Increased awareness of reproductive health and family planning among the population is a primary driver for market growth. Educational campaigns and a greater emphasis on women's health have contributed to more women being informed about contraceptive options, having a significant impact on their choices.

    Moreover, legislative changes aimed at increasing access to contraceptive methods, including insurance coverage mandates, are promoting the utilization of contraceptive drugs. Opportunity exists in the market for innovative contraceptive methods and long-acting reversible contraceptives (LARCs).The growing demand for personalized healthcare solutions creates a pathway for companies to explore new formulations and delivery systems, addressing individual preferences and needs.

    There is also potential in expanding accessibility to underserved populations, particularly in rural areas, through telemedicine and mobile health initiatives. In recent times, there has been a noticeable trend toward more holistic approaches to contraceptive care, incorporating lifestyle factors and mental health into discussions around family planning. This trend reflects a shift in perspective that prioritizes the overall well-being of individuals seeking contraceptive solutions.

    Furthermore, there is an increasing focus on eco-friendly and sustainable contraceptive options, aligning with broader environmental concerns prevalent among consumers today. As these trends evolve, they will shape the dynamics of the US contraceptive drugs market, driving innovations and fostering growth opportunities.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    US Contraceptive Drugs Market Drivers

    Market Segment Insights

    Contraceptive Drugs Market Drug Type Insights

    The US Contraceptive Drugs Market is characterized by a diverse range of drug types, each playing a crucial role in addressing the various family planning needs of the population. Among these, Oral Contraceptives are notably popular due to their convenience and effectiveness, making them a go-to choice for many women. These pills are seen as effective and allow for controlled family planning, catering to different lifestyles and needs. Risk factors such as obesity and age may impact their use, but their accessibility makes them dominant in the market.

    Injectable Contraceptives represent another essential category within the US Contraceptive Drugs Market, appreciated for their long-lasting nature, offering convenience with just a few injections per year. This method not only aids in adherence to the contraception regimen but also provides an effective means to prevent pregnancies, appealing to women looking for reliability without daily attention.

    Implantable Contraceptives have emerged as a significant alternative, situated as a long-term option for women who prefer a "set it and forget it" solution. Their placement under the skin allows for effective contraception for extended periods, emphasizing the importance of innovation in family planning methods, particularly for those seeking a more sustainable and hassle-free option.

    Intrauterine Devices (IUDs) also form a critical aspect of the market, boasting high efficacy rates and a long duration of action, which makes them highly sought after. Women appreciate this option for its low maintenance and minimal systemic effects compared to hormonal methods. The growing acceptance of IUDs reflects a shift in societal attitudes towards long-term contraceptive solutions.

    Emergency Contraceptives hold a unique position within this landscape, providing a crucial backup for unforeseen circumstances. Their presence not only adds an additional layer of security for individuals but also speaks to the ongoing discussions surrounding reproductive rights and access to family planning resources in the US, enabling women to take control of their reproductive health even after an unexpected event occurs.

    Contraceptive Drugs Market Mechanism of Action Insights

    The Mechanism of Action segment within the US Contraceptive Drugs Market holds significant importance as it delineates the different methods employed to prevent pregnancy. This segment is classified into various methodologies, including Hormonal, Barrier, Intrauterine, Surgical, and Natural methods, each playing a crucial role in family planning.

    Hormonal contraceptives, which may involve pills, patches, and injections, are widely utilized due to their effectiveness in regulating menstrual cycles and preventing ovulation. In contrast, Barrier methods primarily rely on physical obstacles, such as condoms and diaphragms, demonstrating high user compliance when properly employed.

    The Intrauterine segment, featuring devices like IUDs, has gained traction due to their long-term efficacy and user-friendliness. Surgical methods, while less common, serve as a permanent solution for those who seek to cease childbearing altogether. Finally, Natural methods are gaining interest for those preferring a non-medical approach. Collectively, these methods contribute to a diverse and evolving landscape, catering to the varied needs of the population and actively influencing the overall US Contraceptive Drugs Market statistics. The market growth is propelled by rising awareness regarding reproductive health, increased accessibility of contraceptives, and societal acceptance of family planning practices within the US.

    Contraceptive Drugs Market Distribution Channel Insights

    The Distribution Channel within the US Contraceptive Drugs Market plays a crucial role in ensuring accessibility to contraceptive options for consumers. Retail pharmacies serve as a primary point of access, providing a wide range of contraceptive products and a helpful consultation process for patients. Online pharmacies are gaining traction due to their convenience, allowing patients to order products discreetly from home, and tend to have a significant presence in the market.

    Hospital pharmacies cater specifically to patients receiving care within the hospital system, often serving a more specialized clientele who may require personalized medication regimes.Specialty clinics focus on reproductive health services, providing specific contraceptive options tailored to individual needs, thereby dominating the sector of targeted care. Direct sales, though less prevalent, are important as they allow healthcare providers or representatives to educate and sell directly to patients, fostering a relationship that can lead to increased trust and improved adherence to prescribed contraceptive methods.

    The importance of each distribution channel varies, with some having a more dominant role in ensuring access to contraceptive drugs while others provide additional support and specialized services, showcasing the diversity within the marketplace and emphasizing the need for various access points in the US healthcare system.

    Contraceptive Drugs Market End User Insights

    The End User segment of the US Contraceptive Drugs Market plays a crucial role in shaping the landscape of contraceptive options available to the population. Women represent a significant portion of this market, as they are the primary users of contraceptive drugs and require tailored solutions that meet their health needs, emphasizing the importance of accessibility and education.

    Healthcare Providers significantly influence the distribution and accessibility of contraceptive methods, serving as key contributors in guiding patients toward the most suitable choices while promoting awareness of various contraceptive options.Additionally, Educational Institutions play a pivotal role in informing and educating the younger population about reproductive health and contraceptive methods, helping to reduce stigma and enhance understanding among students.

    The interplay between these groups contributes to the overall effectiveness and social acceptance of contraceptive methods in the US, with government initiatives frequently supporting educational programs focusing on reproductive health, thereby creating a more informed public. By addressing the unique needs of each End User, the US Contraceptive Drugs Market can continue to advance and adapt to the changing landscape of reproductive health, fostering a supportive environment for responsible family planning and health education.

    Get more detailed insights about US Contraceptive Drugs Market Research Report - Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The US Contraceptive Drugs Market is characterized by a diverse array of pharmaceutical products designed to prevent pregnancy, catering to various consumer needs and preferences. This market has been evolving in response to changing societal attitudes towards reproductive health, increased accessibility to contraceptive options, and growing awareness about family planning methods. Competition within this market is influenced by factors such as regulatory changes, advancements in technology, marketing strategies, and the introduction of innovative products.

    Companies strive to enhance their offerings through research and development, often seeking to gain market share by effectively addressing the specific requirements and preferences of consumers, thus making it a dynamic and responsive segment of the healthcare industry.Teva Pharmaceuticals has established a significant presence within the US Contraceptive Drugs Market, leveraging its extensive portfolio of generic and brand-name contraceptives. The company's strength lies in its ability to offer a wide range of affordable options, which provides an accessible solution for a diverse demographic of consumers seeking various contraceptive methods.

    Teva emphasizes its commitment to quality and safety, ensuring that its products meet stringent regulatory standards while achieving high levels of patient satisfaction. The company's strategic focus on research and development enables it to innovate and expand its product range continually, thereby reinforcing its market position as a leader in cost-effective contraceptive solutions.Bristol Myers Squibb also plays a notable role in the US Contraceptive Drugs Market with its dedicated approach to addressing reproductive health needs. The company has been proactive in developing key products aimed at providing effective contraceptive options, thereby enhancing its relevancy and competitive edge in this sector.

    Bristol Myers Squibb’s strengths include its strong research capabilities, extensive marketing strategies, and the ability to maintain strategic partnerships that improve its distribution network. Furthermore, the company’s commitment to mergers and acquisitions has allowed it to enhance its product offerings and expand its market reach within the US. This approach has positioned Bristol Myers Squibb as a significant player in the contraceptive domain, contributing to improved access and options for consumers across the country.

    Key Companies in the US Contraceptive Drugs Market market include

    Industry Developments

    The US Contraceptive Drugs Market has witnessed several notable developments recently. In September 2023, Teva Pharmaceuticals announced an expansion of its product line, focusing on the launch of new generics, which is expected to enhance accessibility for consumers. Concurrently, Merck reported positive results from clinical trials for its innovative contraceptive applications, signaling a strong upcoming presence in the market.

    Major players like Johnson and Johnson and Pfizer have also been ramping up initiatives to collaborate with health organizations to promote contraceptive awareness and availability. In terms of mergers and acquisitions, Verona Pharma, although not listed among the companies of interest, completed a strategic acquisition in the contraceptive sector in June 2023, echoing a trend towards consolidation in the market.

    Growth in this market has been propelled by an increasing emphasis on family planning and women’s health, influencing valuations across companies such as Bayer and HRA Pharma. In recent years, significant investments in Research and Development have emerged, with AstraZeneca and Novartis leading initiatives aimed at advancing contraceptive technologies. The overall market growth continues to reflect evolving consumer preferences and increasing healthcare accessibility in the United States.

    Market Segmentation

    Contraceptive Drugs Market End User Outlook

    • Women
    • Healthcare Providers
    • Educational Institutions

    Contraceptive Drugs Market Drug Type Outlook

    • Oral Contraceptives
    • Injectable Contraceptives
    • Implantable Contraceptives
    • Intrauterine Devices
    • Emergency Contraceptives

    Contraceptive Drugs Market Mechanism of Action Outlook

    • Hormonal
    • Barrier
    • Intrauterine
    • Surgical
    • Natural

    Contraceptive Drugs Market Distribution Channel Outlook

    • Retail Pharmacies
    • Online Pharmacies
    • Hospital Pharmacies
    • Specialty Clinics
    • Direct Sales

    Report Scope

     
    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 4.65(USD Billion)
    MARKET SIZE 2024 4.87(USD Billion)
    MARKET SIZE 2035 7.2(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 3.622% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Teva Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, Novartis, Merck, HRA Pharma, Perrigo, Pfizer, Amgen, Allergan, Galderma, Johnson and Johnson, Mylan, Bayer, Sun Pharmaceutical
    SEGMENTS COVERED Drug Type, Mechanism of Action, Distribution Channel, End User
    KEY MARKET OPPORTUNITIES Growing demand for eco-friendly options, Increased telehealth for prescriptions, Rising awareness of female empowerment, Expansion of contraceptive access programs, Development of personalized contraceptive solutions
    KEY MARKET DYNAMICS increased demand for birth control, growing awareness of reproductive health, advancements in contraceptive technology, changing regulatory environment, rising popularity of long-acting methods
    COUNTRIES COVERED US

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Get In Touch
    Leave a Comment

    FAQs

    What is the current market size of the US Contraceptive Drugs Market in 2024?

    The US Contraceptive Drugs Market is expected to be valued at 4.87 billion USD in 2024.

    What is the projected market size for the US Contraceptive Drugs Market by 2035?

    By 2035, the US Contraceptive Drugs Market is anticipated to reach 7.2 billion USD.

    What is the expected CAGR for the US Contraceptive Drugs Market from 2025 to 2035?

    The anticipated CAGR for the US Contraceptive Drugs Market from 2025 to 2035 is 3.622 percent.

    Which segment of the US Contraceptive Drugs Market has the highest projected value in 2024?

    Oral Contraceptives is projected to be the highest valued segment at 1.6 billion USD in 2024.

    What will be the market value of Injectable Contraceptives in 2035?

    The market value of Injectable Contraceptives is expected to reach 1.7 billion USD by 2035.

    Who are the major players in the US Contraceptive Drugs Market?

    Key players in the market include Teva Pharmaceuticals, Pfizer, Merck, and AstraZeneca.

    What is the expected growth rate for Intrauterine Devices in the coming years?

    Intrauterine Devices are projected to grow from 0.75 billion USD in 2024 to 1.2 billion USD by 2035.

    What is the projected market size for Emergency Contraceptives in 2035?

    Emergency Contraceptives are expected to be valued at 0.7 billion USD by 2035.

    How does the growth rate for Implantable Contraceptives compare to other segments?

    Implantable Contraceptives are projected to grow from 0.9 billion USD in 2024 to 1.4 billion USD by 2035.

    What key factors are driving growth in the US Contraceptive Drugs Market?

    Growth in the market is driven by increasing awareness and accessibility of contraceptive options.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. US
    59. Contraceptive Drugs Market, BY Drug Type (USD Billion)
    60. Oral
    61. Contraceptives
    62. Injectable Contraceptives
    63. Implantable
    64. Contraceptives
    65. Intrauterine Devices
    66. Emergency
    67. Contraceptives
    68. US Contraceptive
    69. Drugs Market, BY Mechanism of Action (USD Billion)
    70. Hormonal
    71. Barrier
    72. Intrauterine
    73. Surgical
    74. Natural
    75. US
    76. Contraceptive Drugs Market, BY Distribution Channel (USD Billion)
    77. Retail
    78. Pharmacies
    79. Online Pharmacies
    80. Hospital
    81. Pharmacies
    82. Specialty Clinics
    83. Direct
    84. Sales
    85. US Contraceptive Drugs
    86. Market, BY End User (USD Billion)
    87. Women
    88. Healthcare
    89. Providers
    90. Educational Institutions
    91. Competitive Landscape
    92. Overview
    93. Competitive
    94. Analysis
    95. Market share Analysis
    96. Major
    97. Growth Strategy in the Contraceptive Drugs Market
    98. Competitive
    99. Benchmarking
    100. Leading Players in Terms of Number of Developments
    101. in the Contraceptive Drugs Market
    102. Key developments and
    103. growth strategies
    104. New Product Launch/Service Deployment
    105. Merger
    106. & Acquisitions
    107. Joint Ventures
    108. Major
    109. Players Financial Matrix
    110. Sales and Operating Income
    111. Major
    112. Players R&D Expenditure. 2023
    113. Company
    114. Profiles
    115. Teva Pharmaceuticals
    116. Financial
    117. Overview
    118. Products Offered
    119. Key
    120. Developments
    121. SWOT Analysis
    122. Key
    123. Strategies
    124. Bristol Myers Squibb
    125. Financial
    126. Overview
    127. Products Offered
    128. Key
    129. Developments
    130. SWOT Analysis
    131. Key
    132. Strategies
    133. AstraZeneca
    134. Financial
    135. Overview
    136. Products Offered
    137. Key
    138. Developments
    139. SWOT Analysis
    140. Key
    141. Strategies
    142. Novartis
    143. Financial
    144. Overview
    145. Products Offered
    146. Key
    147. Developments
    148. SWOT Analysis
    149. Key
    150. Strategies
    151. Merck
    152. Financial
    153. Overview
    154. Products Offered
    155. Key
    156. Developments
    157. SWOT Analysis
    158. Key
    159. Strategies
    160. HRA Pharma
    161. Financial
    162. Overview
    163. Products Offered
    164. Key
    165. Developments
    166. SWOT Analysis
    167. Key
    168. Strategies
    169. Perrigo
    170. Financial
    171. Overview
    172. Products Offered
    173. Key
    174. Developments
    175. SWOT Analysis
    176. Key
    177. Strategies
    178. Pfizer
    179. Financial
    180. Overview
    181. Products Offered
    182. Key
    183. Developments
    184. SWOT Analysis
    185. Key
    186. Strategies
    187. Amgen
    188. Financial
    189. Overview
    190. Products Offered
    191. Key
    192. Developments
    193. SWOT Analysis
    194. Key
    195. Strategies
    196. Allergan
    197. Financial
    198. Overview
    199. Products Offered
    200. Key
    201. Developments
    202. SWOT Analysis
    203. Key
    204. Strategies
    205. Galderma
    206. Financial
    207. Overview
    208. Products Offered
    209. Key
    210. Developments
    211. SWOT Analysis
    212. Key
    213. Strategies
    214. Johnson and Johnson
    215. Financial
    216. Overview
    217. Products Offered
    218. Key
    219. Developments
    220. SWOT Analysis
    221. Key
    222. Strategies
    223. Mylan
    224. Financial
    225. Overview
    226. Products Offered
    227. Key
    228. Developments
    229. SWOT Analysis
    230. Key
    231. Strategies
    232. Bayer
    233. Financial
    234. Overview
    235. Products Offered
    236. Key
    237. Developments
    238. SWOT Analysis
    239. Key
    240. Strategies
    241. Sun Pharmaceutical
    242. Financial
    243. Overview
    244. Products Offered
    245. Key
    246. Developments
    247. SWOT Analysis
    248. Key
    249. Strategies
    250. References
    251. Related
    252. Reports
    253. LIST
    254. OF ASSUMPTIONS
    255. US Contraceptive Drugs Market SIZE ESTIMATES
    256. & FORECAST, BY DRUG TYPE, 2019-2035 (USD Billions)
    257. US
    258. Contraceptive Drugs Market SIZE ESTIMATES & FORECAST, BY MECHANISM OF ACTION,
    259. 2035 (USD Billions)
    260. US Contraceptive Drugs Market
    261. SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD Billions)
    262. US
    263. Contraceptive Drugs Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035
    264. (USD Billions)
    265. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    266. ACQUISITION/PARTNERSHIP
    267. LIST
    268. Of figures
    269. MARKET SYNOPSIS
    270. US
    271. CONTRACEPTIVE DRUGS MARKET ANALYSIS BY DRUG TYPE
    272. US CONTRACEPTIVE
    273. DRUGS MARKET ANALYSIS BY MECHANISM OF ACTION
    274. US CONTRACEPTIVE
    275. DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    276. US CONTRACEPTIVE
    277. DRUGS MARKET ANALYSIS BY END USER
    278. KEY BUYING CRITERIA
    279. OF CONTRACEPTIVE DRUGS MARKET
    280. RESEARCH PROCESS OF MRFR
    281. DRO
    282. ANALYSIS OF CONTRACEPTIVE DRUGS MARKET
    283. DRIVERS IMPACT
    284. ANALYSIS: CONTRACEPTIVE DRUGS MARKET
    285. RESTRAINTS IMPACT
    286. ANALYSIS: CONTRACEPTIVE DRUGS MARKET
    287. SUPPLY / VALUE CHAIN:
    288. CONTRACEPTIVE DRUGS MARKET
    289. CONTRACEPTIVE DRUGS MARKET,
    290. BY DRUG TYPE, 2025 (% SHARE)
    291. CONTRACEPTIVE DRUGS MARKET,
    292. BY DRUG TYPE, 2019 TO 2035 (USD Billions)
    293. CONTRACEPTIVE
    294. DRUGS MARKET, BY MECHANISM OF ACTION, 2025 (% SHARE)
    295. CONTRACEPTIVE
    296. DRUGS MARKET, BY MECHANISM OF ACTION, 2019 TO 2035 (USD Billions)
    297. CONTRACEPTIVE
    298. DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2025 (% SHARE)
    299. CONTRACEPTIVE
    300. DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019 TO 2035 (USD Billions)
    301. CONTRACEPTIVE
    302. DRUGS MARKET, BY END USER, 2025 (% SHARE)
    303. CONTRACEPTIVE
    304. DRUGS MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    305. BENCHMARKING
    306. OF MAJOR COMPETITORS

    US Contraceptive Drugs Market Segmentation

    • Contraceptive Drugs Market By Drug Type (USD Billion, 2019-2035)

      • Oral Contraceptives
      • Injectable Contraceptives
      • Implantable Contraceptives
      • Intrauterine Devices
      • Emergency Contraceptives

     

    • Contraceptive Drugs Market By Mechanism of Action (USD Billion, 2019-2035)

      • Hormonal
      • Barrier
      • Intrauterine
      • Surgical
      • Natural

     

    • Contraceptive Drugs Market By Distribution Channel (USD Billion, 2019-2035)

      • Retail Pharmacies
      • Online Pharmacies
      • Hospital Pharmacies
      • Specialty Clinics
      • Direct Sales

     

    • Contraceptive Drugs Market By End User (USD Billion, 2019-2035)

      • Women
      • Healthcare Providers
      • Educational Institutions

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027